{"id":347893,"date":"2025-10-12T18:11:05","date_gmt":"2025-10-12T12:41:05","guid":{"rendered":"https:\/\/forumias.com\/blog\/?page_id=347893"},"modified":"2025-10-12T18:11:05","modified_gmt":"2025-10-12T12:41:05","slug":"answered-critically-analyze-the-role-of-regulatory-and-oversight-gaps-in-recurrent-public-health-tragedies-like-contaminated-medicines-examine-the-reforms-needed-to-strengthen-drug-control-mechanis","status":"publish","type":"page","link":"https:\/\/forumias.com\/blog\/answered-critically-analyze-the-role-of-regulatory-and-oversight-gaps-in-recurrent-public-health-tragedies-like-contaminated-medicines-examine-the-reforms-needed-to-strengthen-drug-control-mechanis\/","title":{"rendered":"[Answered] Critically analyze the role of regulatory and oversight gaps in recurrent public health tragedies like contaminated medicines. Examine the reforms needed to strengthen drug control mechanisms."},"content":{"rendered":"

Introduction<\/strong><\/h2>\n

According to the WHO (2023), 1 in 10 medical products<\/strong> in low- and middle-income countries is substandard or falsified. Indias recurring contaminated syrup tragedies expose deep regulatory and institutional fragilities.<\/p>\n

The Recurring Public Health Tragedy: A Regulatory Failure<\/strong><\/h2>\n
    \n
  1. Historical continuity:<\/strong> Since 1986, India has faced at least five major diethylene glycol (DEG)<\/strong> contamination episodes \u2014 from Mumbais J.J. Hospital deaths to incidents in The Gambia (2022) and Uzbekistan (2023).<\/li>\n
  2. Recent episode:<\/strong> The 2024 Coldrif cough syrup deaths<\/strong> in Madhya Pradesh and Rajasthan again exposed the lack of proactive quality assurance. DEG, a toxic solvent used industrially, continues to leak into pharmaceutical supply chains.<\/li>\n
  3. Systemic lapse:<\/strong> Instead of targeting negligent manufacturers, enforcement agencies often scapegoat frontline practitioners\u2014highlighted by the arrest of a government paediatrician<\/strong> instead of accountability within drug regulatory frameworks.<\/li>\n<\/ol>\n

    Role of Regulatory and Oversight Gaps<\/strong><\/h2>\n
      \n
    1. Fragmented regulatory structure:<\/strong> India has a dual regulatory system<\/strong> \u2014 the Central Drugs Standard Control Organisation (CDSCO)<\/strong> and State Drug Controllers<\/strong> \u2014 leading to overlaps and poor coordination. State authorities often lack laboratory capacity, manpower, and autonomy.<\/li>\n
    2. Lax enforcement of standards:<\/strong> The Schedule M<\/strong> (Good Manufacturing Practices) guidelines remain poorly implemented; only 15% of licensed units reportedly comply with full GMP norms (PIB, 2023).<\/li>\n
    3. Inadequate surveillance mechanisms:<\/strong> The Pharmacovigilance Programme of India (PvPI)<\/strong> lacks timely recall mechanisms and post-market surveillance. Risk-based inspections are infrequent and often reactive, following deaths rather than anticipating failures.<\/li>\n
    4. Weak international credibility:<\/strong> The WHO global alert (2022)<\/strong> on Indian-made syrups linked to child deaths in The Gambia and Uzbekistan dented Indias image as the pharmacy of the Global South. Export regulatory oversight<\/strong> is inconsistent \u2014 many small firms bypass stringent testing protocols for cost efficiency.<\/li>\n
    5. Ethical and governance deficit:<\/strong> The absence of corporate accountability<\/strong> and public disclosure norms<\/strong> encourages underreporting. Lack of whistleblower protection further erodes institutional transparency.<\/li>\n<\/ol>\n

      Broader Public Health and Ethical Implications<\/strong><\/h2>\n
        \n
      1. Violation of Right to Health:<\/strong> As recognized in Paschim Banga Khet Mazdoor Samity v. State of West Bengal (1996),<\/strong> access to safe medicines is integral to Article 21s Right to Life.<\/li>\n
      2. Erosion of public trust:<\/strong> Repeated incidents weaken public confidence in both domestic and export drug markets, undermining health diplomacy.<\/li>\n
      3. One Health dimension:<\/strong> Poor pharmaceutical waste management and chemical contamination have spillover effects on ecosystems and food safety, expanding the risk to zoonotic health.<\/li>\n<\/ol>\n

        Reform Measures to Strengthen Drug Control Mechanisms<\/strong><\/h2>\n
          \n
        1. Institutional restructuring:<\/strong> Establish a National Drug Authority<\/strong> on the lines of the U.S. FDA<\/strong>, ensuring uniform licensing, inspection, and recall powers.<\/li>\n
        2. Digital and AI integration:<\/strong> Use blockchain-based supply chain monitoring<\/strong> and AI-enabled pharmacovigilance<\/strong> to detect anomalies in real-time.<\/li>\n
        3. Legislative modernization:<\/strong> Expedite passage of the Drugs, Medical Devices and Cosmetics Bill, 2023<\/strong>, which mandates stringent compliance, penalizes non-conformity, and enhances recall provisions.<\/li>\n
        4. Capacity building:<\/strong> Enhance testing infrastructure\u2014India has only 38 central and state drug laboratories<\/strong> for over 10,000 manufacturing units.<\/li>\n
        5. International collaboration:<\/strong> Align domestic standards with WHO-GMP certification<\/strong> and PIC\/S guidelines<\/strong> to ensure global credibility.<\/li>\n
        6. Public transparency:<\/strong> A publicly accessible Drug Quality Index<\/strong> can ensure accountability and empower consumers.<\/li>\n<\/ol>\n

          Conclusion<\/strong><\/h2>\n

          As Amartya Sens Development as Freedom asserts<\/strong>, real development expands human capabilities.<\/strong> Ensuring drug safety through robust regulation embodies freedom from preventable suffering\u2014a moral and constitutional imperative for Indias health sovereignty.<\/p>\n","protected":false},"excerpt":{"rendered":"

          Introduction According to the WHO (2023), 1 in 10 medical products in low- and middle-income countries is substandard or falsified. Indias recurring contaminated syrup tragedies expose deep regulatory and institutional fragilities. The Recurring Public Health Tragedy: A Regulatory Failure Historical continuity: Since 1986, India has faced at least five major diethylene glycol (DEG) contamination episodes… Continue reading [Answered] Critically analyze the role of regulatory and oversight gaps in recurrent public health tragedies like contaminated medicines. Examine the reforms needed to strengthen drug control mechanisms.<\/span><\/a><\/p>\n","protected":false},"author":10320,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"jetpack_post_was_ever_published":false,"footnotes":""},"class_list":["post-347893","page","type-page","status-publish","hentry","entry"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/pages\/347893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/users\/10320"}],"replies":[{"embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/comments?post=347893"}],"version-history":[{"count":0,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/pages\/347893\/revisions"}],"wp:attachment":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/media?parent=347893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}